3 ms·
The trial tested psilocybin combined with therapy. This isn’t equivalent to ad-hoc self treatment with mushrooms. They noticed a response to psilocybin+therapy
by PragmaticPulp 5y ago
The trial tested psilocybin combined with therapy. This isn’t equivalent to ad-hoc self treatment with mushrooms.
They noticed a response to psilocybin+therapy in about 20-25% of patients depending on the criteria for “sustained response”:
> The protocol-defined sustained response* up to week 12 was double, with 20.3% of patients in the 25mg group
It’s also notable that about 5% of the psilocybin receivers experienced severe adverse events including suicidal ideation:
> There were 12 patients who reported treatment-emergent serious adverse events (TESAEs). These TESAEs included suicidal behaviour, intentional self-injury, and suicidal ideation
- JohnJamesRambo 5y agoThis sounds pretty crappy right? If I'm understanding the numbers, 25% response is about like what we get with a placebo in most studies if my memory is correct. It sounds like they were tripping balls on 25 mg, so this is definitely in active placebo range. From my memory: Placebo is about 25%. Antidepressants about 35% response rate. Active placebo of something like atropine which makes you feel weird but isn't an antidepressant has about a 35% response rate. https://blogs.scientificamerican.com/cross-check/are-antidepressants-just-placebos-with-side-effects/ https://blogs.scientificamerican.com/cross-check/are-antidep...
- drooby 5y agoI’m not sure if it makes a difference, but this study was conducted on _treatment resistant_ patients.